Connect with us

BioPharma

Asia Broadband (OTCMKTS: AABB) Heats Up as Crypto Operator Reports $1.1 million + in AABBG Gold Token sales Over Past 4 Weeks & Prepares for Imminent Launch of its AABBExchange Crypto Exchange

Published

on

Asia Broadband (OTCMKTS: AABB) has been highly active in recent trading seeing a new intra-day high near $0.30 per share after the Company reported it has recorded over $1.1 million in AABBG Gold Token sales within the recent 4-week period ending November 15, in advance of the imminent launch of the proprietary cryptocurrency exchange. AABB’s primary goal for the AABBG token is to become a worldwide standard of exchange that is secured and trusted with gold backing, by progressively expanding token circulation to the primary sales markets of North America and Europe and expand globally to other predominant and high growth market areas. The launch of the Company’s AABB Wallet in March 2021 introduced its AABBG token’s initial release to the market that is backed by $30 million in physical gold the Company currently holds. We have previously reported on the Company’s sale of its mining operations in the Guerrero Gold Belt (GGB), Mexico, that netted them $82 million, which has funded all of this. As of the latest 10Q filed earlier this month the Company has $70,945,697 in the treasury. 

Investors continue to heavily accumulate AABB as the launch of its proprietary cryptocurrency exchange is imminent. The Exchange project has evolved and grown immensely in recent months to vastly improve the finished product. The new platform of the Exchange, the BCGateway, is now complete and allows for an expanding number of cryptocurrencies to be added which currently stands at 82 cryptocurrencies to purchase the AABBG token in the AABB Wallet, as shown on the new Exchange website AABBExchange.com. Trade pairs for exchange are also being created from this growing list of cryptocurrencies. AABB skyrocketed from double zeroes to highs of $0.659 per share earlier this year and speculators are looking for a return to previous highs. AABB has momentum, huge liquidity and legions of new shareholders, many of them powerful players in small caps bidding up the price; a break into the $0.30s marks the next leg up with a gap to fill to $0.659 per share. 

Asia Broadband (OTCMKTS: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertical integration approach to sales transactions is the unique strength of AABB that differentiates the Company and creates distinctive value for shareholders. Additionally, the Company has recently released its AABBG freshly minted mine-to-token gold-backed cryptocurrency and is developing its own proprietary digital exchange. AABB expects its token to become a world-wide standard of exchange that is stable, secured and trusted with gold backing, while having the added benefit of demand-based price appreciation. These are unique and outstanding qualities relative to other cryptocurrencies. 

Earlier this year AABB released its long-awaited gold-backed ERC-20 token which it expects will become a world-wide standard of exchange that is secured and trusted with gold backing. Subsequent to the closing the 2020 year-end, AABB completed the sale of its mining operations in the Guerrero Gold Belt (GGB), Mexico, for $82 million, and the Company has used these resources to fund the launch of its new ERC-20 token. The Company’s latest issued filing shows it is virtually debt free with $7.8 million in the treasury and $10.6 million in revenues for the 9 months ended September 30, 2020. According to Asia broadband the AABB Gold token (AABBG) is backed 100% by physical gold held by the Company in several high security, private locations in Mexico. The Company will continue to back the token 100% by additional physical gold acquired from future mining production and gold purchased from cash reserves or credit. The initial token release was backed by $30 million in physical gold the Company currently holds. 

In order to buy the AABB Gold token (AABBG), purchasers must download the AABB Wallet and register through the Android Google Play and Apple App Store on their smartphones or through the AABBGoldToken.com website. Within the AABB Wallet, the token will only be available for purchase in exchange for other major cryptocurrencies such as Bitcoin, Ethereum and Litecoin. Therefore, purchasers will need to hold existing cryptocurrency in any third-party wallet such as Coinbase or Binance. Purchasers will then deposit cryptocurrency from their third-party wallet into their AABB Wallet to exchange and purchase the AABB Gold token (AABBG) for the current 0.1 gram of gold price plus a 2% transaction fee. 

Microcapdaily has been writing about AABB for quite some times now starting back in July 2020 when the stock was in the doubled zeroes long before it skyrocketed to $0.659 highs back in March of this year reporting at the time: “AABB said it has initiated the planning and preparation process to create a development program for the Company’s new gold mine property acquisition in Colombia, South America.  From the three site visits to the property prior to the Colombia travel ban in March, the Company completed significant groundwork and accumulated considerable data on the property during the due diligence process prior to the property acquisition.  AABB has been utilizing this data to construct a further groundwork plan and staged development program, which is set to begin after the Colombia travel ban is lifted in the next several months. The gold mine property consists of 912 hectares and includes an artisan mining site that has historically produced gold and silver.” 

Since then, AABB completed the sale of its mining operations in the Guerrero Gold Belt (GGB), Mexico, for $82 million, and the Company has used these resources to fund the launch of its new ERC-20 token.

https://twitter.com/fishbass429/status/1461462563783426055

To Find out the inside Scoop on AABB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

AABB

Earlier this month Asia broadband established a corporate presence and satellite office in El Salvador to serve as the Company’s Central and South American operations hub in preparation for the upcoming Exchange launch. The Company is also in discussions to explore the creation of a cryptocurrency mining facility in El Salvador powered by geothermal energy. Recently, the Company registered a subsidiary in El Salvador, AABBG Exchange Sociedad Anonima De Capital Variable, to form the foundation of the new business development and marketing facility. An initial team of support staff has been assembled to continue building demand for the AABBG token and Exchange in Latin America. 

In recent months, the AABB management team has been traveling regularly to El Salvador to complete the setup of the new subsidiary, office and communications center. During this time, the AABB wallet and Exchange has continued to be very well received by the local business community in El Salvador, validating the Company’s business plans within the country and expansion into the Latin American market. The Company is diligently targeting major Salvadoran retailers to engage in acceptance and processing agreements for customer purchases with AABBG and expand Exchange awareness. The ongoing business development program is designed with substantial commission and discount incentives for retailers and customers to fulfill transactions with AABBG, facilitate circulation expansion and use of the Exchange. 

The stock has been seeing some action since the Company reported it has recorded over $1.1 million in AABBG Gold Token sales within the recent 4 week period ending November 15, in advance of the imminent launch of the proprietary cryptocurrency exchange. AABB’s primary goal for the AABBG token is to become a worldwide standard of exchange that is secured and trusted with gold backing, by progressively expanding token circulation to the primary sales markets of North America and Europe and expand globally to other predominant and high growth market areas. AABB embraces a pioneering philosophy with its truly unique Mine-to-Token vertical integration operational approach that strives toward complete independence from FIAT currency. 

The launch of the Company’s AABB Wallet in March 2021 introduced its AABBG token’s initial release to the market that is backed by $30 million in physical gold the Company currently holds. Further token releases will continue to be backed 100% by additional physical gold acquired from the Company’s future mining production, gold purchased from cash reserves or credit. At today’s market price of gold, the one-tenth (0.1) gram of gold backing the AABBG token price is approximately $5.96 USD. The token price is tied to and supported by the Company at the market price of gold at a minimum. As the price of gold fluctuates, the minimum supported price of the AABBG token will increase or decrease. However, the potential upside price of the token will be driven by market demand after the Exchange launch. 

Additionally, the Company is continuing to collaborate diligently with the Exchange developer to integrate and test the network of components in final preparations to soon release the proprietary cryptocurrency exchange within the AABB Wallet. Just recently, over 100 cryptocurrency Exchange trading pairs have been added into to the BCGateway platform. The Exchange project has evolved and grown immensely in recent months to vastly improve the finished product. Many new features and capabilities have been added to expand functionality, usability, module additions and market penetration including the web version, Spanish language version and a new Exchange website. AABB management and the development team are thrilled in anticipation of the approaching Exchange launch. 

 For More on AABB Subscribe Right Now

Asia Broadband has been highly active in recent trading seeing a new intra-day high near $0.30 per share after the Company reported it has recorded over $1.1 million in AABBG Gold Token sales within the recent 4-week period ending November 15, in advance of the imminent launch of the proprietary cryptocurrency exchange. AABB’s primary goal for the AABBG token is to become a worldwide standard of exchange that is secured and trusted with gold backing, by progressively expanding token circulation to the primary sales markets of North America and Europe and expand globally to other predominant and high growth market areas. The launch of the Company’s AABB Wallet in March 2021 introduced its AABBG token’s initial release to the market that is backed by $30 million in physical gold the Company currently holds. We have previously reported on the Company’s sale of its mining operations in the Guerrero Gold Belt (GGB), Mexico, that netted them $82 million, which has funded all of this. As of the latest 10Q filed earlier this month the Company has $70,945,697 in the treasury. (very rare numbers for an otc stock) Investors continue to heavily accumulate AABB as the launch of its proprietary cryptocurrency exchange is imminent. The Exchange project has evolved and grown immensely in recent months to vastly improve the finished product. The new platform of the Exchange, the BCGateway, is now complete and allows for an expanding number of cryptocurrencies to be added which currently stands at 82 cryptocurrencies to purchase the AABBG token in the AABB Wallet, as shown on the new Exchange website AABBExchange.com. Trade pairs for exchange are also being created from this growing list of cryptocurrencies. AABB skyrocketed from double zeroes to highs of $0.659 per share earlier this year and speculators are looking for a return to previous highs. AABB has momentum, huge liquidity and legions of new shareholders, many of them powerful players in small caps bidding up the price; a break into the $0.30s marks the next leg up with a gap to fill to $0.659 per share. We will be updating on AABB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AABB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AABB either long or short and we have not been compensated for this article.

 

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.